Ionizable Polymer Nucleic Acid Vehicles for Targeted mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing mRNA delivery vehicles face issues with rapid diffusion to non-target sites (off-target effect) and high immunogenicity, leading to side effects such as myocarditis and pericarditis, necessitating the development of a polymer-based delivery system with high efficiency, low off-target effect, and reduced immunogenicity.
Innovation Solution
A polymer-based nucleic acid delivery vehicle with pH sensitivity, composed of specific repeating units and PEG-containing moieties, forms a complex with nucleic acids to enhance delivery efficiency and duration, avoiding lipid nanoparticles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If lipid nanoparticles are used as mRNA delivery vehicles, then mRNA delivery efficiency is improved, but off-target effects and immunogenicity increase
Solution Approach 1:
The patent changes the chemical composition parameters of the delivery vehicle from lipid-based to polymer-based systems with specific functional groups (carboxyl, hydroxyl, amino). This parameter change maintains delivery efficiency while reducing immunogenicity and off-target effects by altering the material properties of the delivery system.
Solution Approach 2:
The patent employs composite polymer structures combining multiple functional moieties (carboxyl groups for complexation, hydroxyl groups for stabilization, amino groups for endosomal escape) within a single delivery vehicle. This composite approach achieves high delivery efficiency while minimizing harmful effects through synergistic functional groups.
2Duration of action of moving object
If mRNA is delivered to achieve sustained protein production, then therapeutic effect duration is improved, but immunogenicity increases causing side effects
Solution Approach 1:
The patent modifies the delivery vehicle material parameters from lipids to biocompatible polymers with specific functional groups, enabling sustained mRNA release and prolonged protein production while reducing immunogenicity and adverse reactions.
Solution Approach 2:
The patent uses biodegradable polymer materials that temporarily perform their delivery function and then degrade, providing sustained therapeutic effect without long-term immunogenicity. The polymer vehicle is designed to be transient, completing its function and degrading to eliminate harmful effects.
3Reliability
If multiple vaccine doses are administered to overcome waning immunity, then immune response is improved, but cumulative side effects increase
Solution Approach 1:
The patent changes the delivery vehicle to polymer-based systems with optimized functional group ratios, achieving reliable and durable immune response that reduces the need for multiple doses, thereby minimizing cumulative side effects from repeated administrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer-based delivery vehicle achieves high nucleic acid delivery efficiency with reduced side effects, allowing targeted delivery and sustained expression, suitable for therapeutic applications and mRNA vaccines.
Implementation Method 1
the polymer according to the present invention can provide high mRNA delivery efficiency through pH sensitivity
Implementation Method 2
a polymer-based nucleic acid molecule delivery vehicle having an ionization moiety
Data Source
AI summary
Provided is a polymer-based nucleic acid molecule (e.g., mRNA) delivery vehicle having an ionizable moiety. Specifically, the present invention provides a novel polymer capable of delivering all negatively charged genetic materials to a desired site according to the monomers and the length of the polymer. The polymer according to the present invention can be effectively used in gene therapeutic agents or vaccines comprising genetic material, such as mRNA, for therapeutic or preventive purposes.